These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND HER1, YOR227W
50 results:

  • 1. Assessment of her1 (rs11543848) and HER2 (rs1136201) polymorphism and their association with colorectal cancer susceptibility in Khyber Pakhtunkhwa, Pakistan.
    Ullah A; Khan BM; Khan NU; Muntaha ST; Khan S; Khan AU; Almutairi MH; Ali I
    Mol Biol Rep; 2023 Dec; 51(1):1. PubMed ID: 38040921
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Based on lapatinib innovative near-infrared fluorescent probes targeting her1/HER2 for in vivo tumors imaging.
    Li C; Lin Q; Hu F; Bao R; Cai H; Gu Y
    Biosens Bioelectron; 2022 Oct; 214():114503. PubMed ID: 35779413
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in colorectal cancer.
    Rau A; Janssen N; Kühl L; Sell T; Kalmykova S; Mürdter TE; Dahlke MH; Sers C; Morkel M; Schwab M; Kontermann RE; Olayioye MA
    Mol Cancer Ther; 2022 May; 21(5):799-809. PubMed ID: 35247930
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.
    Berlin J; Tolcher AW; Ding C; Whisenant JG; Horak ID; Wood DL; Nadler PI; Hansen UH; Lantto J; Skartved NJØ; Pedersen MW; Patnaik A
    Invest New Drugs; 2022 Jun; 40(3):586-595. PubMed ID: 35113285
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Identification of 6 Hub Proteins and Protein Risk Signature of colorectal cancer.
    Yue T; Liu C; Zhu J; Huang Z; Guo S; Zhang Y; Xu H; Liu Y; Wang P; Chen S
    Biomed Res Int; 2020; 2020():6135060. PubMed ID: 33376727
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Exploring the radiosensitizing potential of AZD8931: a pilot study on the human LoVo colorectal cancer cell line.
    Antognelli C; Palumbo I; Piattoni S; Calzuola M; Del Papa B; Talesa VN; Aristei C
    Int J Radiat Biol; 2020 Nov; 96(11):1504-1512. PubMed ID: 32910714
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides.
    Hong ST; Lin H; Wang CS; Chang CH; Lin AM; Yang JC; Lo YL
    J Nanobiotechnology; 2019 Aug; 17(1):89. PubMed ID: 31426807
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Lapatinib.
    Voigtlaender M; Schneider-Merck T; Trepel M
    Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Exploration of a F(ab')
    Milenic DE; Kim YS; Baidoo KE; Wong KJ; Barkley R; Delgado J; Brechbiel MW
    Cancer Biother Radiopharm; 2018 Jun; 33(5):182-193. PubMed ID: 29916748
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Radiolabeled F(ab')
    Bellaye PS; Moreau M; Raguin O; Oudot A; Bernhard C; Vrigneaud JM; Dumont L; Vandroux D; Denat F; Cochet A; Brunotte F; Collin B
    Clin Transl Oncol; 2018 Dec; 20(12):1557-1570. PubMed ID: 29777377
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced colorectal cancer.
    Seligmann JF; Hatch AJ; Richman SD; Elliott F; Jacobs B; Brown S; Hurwitz H; Barrett JH; Quirke P; Nixon AB; Seymour MT
    JAMA Oncol; 2018 Apr; 4(4):564-568. PubMed ID: 29075780
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Neratinib: First Global Approval.
    Deeks ED
    Drugs; 2017 Oct; 77(15):1695-1704. PubMed ID: 28884417
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. The prospect of patritumab for treating non-small cell lung cancer.
    Horinouchi H
    Expert Opin Biol Ther; 2016 Dec; 16(12):1549-1555. PubMed ID: 27744717
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor.
    Tiwari SR; Mishra P; Abraham J
    Clin Breast Cancer; 2016 Oct; 16(5):344-348. PubMed ID: 27405796
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. HER family receptor expression and prognosis in pancreatic cancer.
    Bittoni A; Mandolesi A; Andrikou K; Santoni M; Alfonsi S; Lanese A; Loretelli C; Pellei C; Piva F; Scarpelli M; Cascinu S
    Int J Biol Markers; 2015 Jul; 30(3):e327-32. PubMed ID: 26109364
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.
    Lee J; Jain A; Kim P; Lee T; Kuller A; Princen F; In-GuDo ; Kim SH; Park JO; Park YS; Singh S; Kim HC
    PLoS One; 2014; 9(8):e103551. PubMed ID: 25090459
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Epidermal growth factor receptor inhibitors: coming of age.
    Mahipal A; Kothari N; Gupta S
    Cancer Control; 2014 Jan; 21(1):74-9. PubMed ID: 24357745
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.
    Foy KC; Wygle RM; Miller MJ; Overholser JP; Bekaii-Saab T; Kaumaya PT
    J Immunol; 2013 Jul; 191(1):217-27. PubMed ID: 23698748
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for her1-expressing carcinomas.
    Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
    Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
    [TBL] [Abstract] [Full Text] [Related]  

    [Next]

    of 3.